# Eli Lilly reported first-quarter adjusted earnings of $8.55 per share.

*biotech · news · 2026-04-30 · Benzinga*

## Key points

- Eli Lilly's Q1 sales grew 56% year over year, exceeding analyst expectations by over $2 billion.
- FDA approved Foundayo, the only GLP-1 pill usable at any time without food or water restrictions.
- Eli Lilly raised 2026 sales guidance to $82–$85 billion, above Wall Street estimates.
- The company announced acquisitions of Kelonia Therapeutics and Ajax Therapeutics totaling up to $9.3 billion.

**Companies:** Eli Lilly, Kelonia Therapeutics Inc., Ajax Therapeutics Inc.
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/markets/earnings/26/04/52180776/eli-lilly-raises-2026-outlook-on-strong-mounjaro-and-zepbound-demand)

---

Canonical: https://newsio.io/n/efeadaa4-b3cf-4099-a932-fde6781aa630/eli-lilly-reported-first-quarter-adjusted-earnings-of-8-55-per-share-the-company
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works